Stockscreener 앱 받기
11.26
12.17%
-1.56
시간 외 거래:
11.19
-0.07
-0.62%
전일 마감가:
$12.82
열려 있는:
$12.71
하루 거래량:
9.87M
Relative Volume:
0.79
시가총액:
$1.86B
수익:
$596.34M
순이익/손실:
$-87.84M
주가수익비율:
-18.85
EPS:
-0.5975
순현금흐름:
$-97.62M
1주 성능:
-11.69%
1개월 성능:
+20.43%
6개월 성능:
+30.32%
1년 성능:
+32.78%
1일 변동 폭
$11.11
$12.84
1주일 범위
$11.11
$13.34
52주 변동 폭
$6.20
$13.38
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
11.26 | 1.86B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax, Inc. Stock 12‑Month Price Target Raised to $15, Implies 19% Upside - TradingView
NVAX Maintained by Citigroup -- Price Target Raised to $8.00 - GuruFocus
Lobbying Update: $120,000 of NOVAVAX INC lobbying was just disclosed - Quiver Quantitative
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Zacks Investment Research
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada
Novavax Inc (Coinbase Tokenized Stock) - CryptoRank
Novavax, Inc.: Revenue and Earnings Analysts Forecasts Revisions | NVV1 | US6700024010 - marketscreener.com
Novavax, Inc. (NVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax Inc. Stock Rises 15.8%, Outperforms Peers - Webull
Novavax Inc (Coinbase Tokenized Stock) Analytics - CryptoRank
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies - Yahoo Finance
NVAX Stock Grinds Higher As Traders Watch Volatile Rebound - Timothy Sykes
Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside - TradingView
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax: Sell The False Plague Breakout (NASDAQ:NVAX) - Seeking Alpha
Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade - Yahoo Finance
Should Novavax’s Headline-Driven Volatility Around Russia Health Scare Require Action From NVAX Investors? - Yahoo Finance
Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks - Seeking Alpha
Novavax Inc (Coinbase Tokenized Stock) Price | NVAXc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Novavax Inc Tokenized Stock (Coinbase) price today, NVAXc to USD live price, marketcap and chart - CoinMarketCap
Transcript: Novavax Q2 2026 Earnings Conference Call - Benzinga
Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
NVAX Stock Slides As Momentum Traders Refocus On Fundamentals - StocksToTrade
Novavax Stock Falls Back: What's Going On? - Benzinga
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher - Yahoo Finance
Novavax, Moderna cool as WHO downplays plague-related death in Russia - Seeking Alpha
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Yahoo Finance
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety - Benzinga
Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today - Benzinga
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Shorts on Edge as Russia Plague Fears Spread - Benzinga
Novavax, Inc. (NVAX) options chain - Yahoo Finance UK
Novavax, Inc. (NVV1.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
NVAX: Daily Falling Wedge Setup Eyeing $11.13 Ahead of Q3 for NASDAQ:NVAX by TaxpayerTrades - TradingView
Enterprise value to EBIT forward of Novavax, Inc. – BX:NVV1 - tradingview.com
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ruxandra Draghia Akli | Former Officer |
May 07 '26 |
Proposed Sale |
9.87 |
30,000 |
296,083 |
0 |
| Newton Charles W. | Director |
Apr 25 '26 |
Option Exercise |
0.00 |
9,520 |
0 |
9,520 |
| Shiver John W. | Director |
Mar 10 '26 |
Option Exercise |
0.00 |
7,947 |
0 |
7,947 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
3.09%
자본화:
|
볼륨(24시간):